Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended		9 Months Ended
	Jan. 11, 2022	May 14, 2021	May 30, 2019	Mar. 28, 2019	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2019	Dec. 10, 2015
Renumeration amount					$ 6,000
Consideration amount	$ 657,640				78,889
First payment owed	$ 145,000				46,422
Attorney's fees					$ 235,886
Monthly amount received common stock equivalent		$ 3,750
Monthly amount received common stock equivalent by consultant		1,375
Interest rate					10.00%
Stock options grant					10,000
Consulting services valued					$ 18,946
Compensation for services, description					As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) one consultant shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month.
Monthly remuneration amount		$ 3,500
Option [Member]
Stock options description					(i) Company shall grant 10,000 incentive Stock Options upon achievement of U.S. $500,000 collected gross revenues, (ii) Company shall grant 20,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,000,000 collected gross revenues, (iii) Company shall grant 30,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,500,000 collected gross revenues, (iv) Company shall grant 40,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $2,000,000 collected gross revenues.
Galligan Subscription and Royalty Agreement [Member]
Common stock, Shares issued				200,000
Subscription and Royalty Agreement				$ 3,000,000
Royality percentage minimum				10.00%
Royality percentage maximum				15.00%
Lucido Subscription and Royalty Agreement [Member]
Royality percentage minimum					10.00%
Royality percentage maximum					15.00%
Purchase price					$ 15.00
Common stock					200,000
Revenue per share					$ 37.50
Gross revenue per share					$ 25.00
Percent of aggregate purchase price					65.00%
Development and expansion expenses amount					$ 3,000,000
Alpine Creek [Member]
Royalty due					$ 91	$ 91
Total consideration amount						$ 1,531,926
Payables to Alpine Creek								$ 1,215,000
Payable commitment description					On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. As of September 30, 2022 and December 31, 2021, there are no payments due
Payable per treatment sold								$ 100
Profit holding percentage								50.00%
Lucido [Member]
Common stock, Shares issued				200,000
Charles River Laboratories, Inc. [Member]
Consideration amount			$ 3,024,476
Remaining commitment					$ 28,936
BICX Holding Company LLC [Member]
Common stock issued upon convertible debt					2,227,575
Convertible Promissory Note							$ 4,160,000
Conversion agreement description					Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment.
Issuance price					$ 2.00
Amount due to investor					$ 1,138,157
Minimum [Member]
Remuneration amount					10,000
Maximum [Member]
Remuneration amount					$ 12,500